of these subcategories adds additional degrees of variation, potentially accounting for the relatively indolent behavior of some LGGs and the comparative aggressiveness of others. 12, 16, 40, 41, 43, 46 Among WHO Grade II tumors, variations in tumor biology can correspond to differences in clinical behavior, as evidenced by LGG imaging studies that highlight predictive patterns of tumor morphology, metabolism, and physiology corresponding to distinct patient outcomes. 8, 15, 37, 40, 44, 45, 48 Thus, studies that combine oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas to identify prognostic factors are almost certainly pooling disparate biological entities and inadvertently obscuring dissimilar patient outcomes and tumor effects. To better understand this phenomenon, we postulated that the impact of microsurgical resection on LGG transformation is driven by tumor biology and, therefore, subject to the homogeneity of the tumor population. Here, we examine a uniform cohort of patients with pure oligodendroglioma to assess the impact of EOR on overall survival (OS), progression-free survival (PFS), and MPFS.
Methods

Clinical Material
Adult patients (age ≥ 18 years) who underwent initial surgery at Barrow Neurological Institute (BNI) for a WHO Grade II oligodendroglioma between 1999 and 2010 and who underwent preoperative and immediately postoperative MRI were identified. Microsurgical resection was performed with the assistance of StealthStation Treon neuronavigation (Medtronic, Inc.) and Zeiss OPMI Pentero microscopes (Carl Zeiss Surgical GmbH). Patients undergoing biopsy only were excluded because this small subset of cases typically had complicating factors, and their inclusion would have inappropriately biased the results. Patients with gemistocytic histology 20 or gliomatosis cerebri were also excluded. Central pathology review was performed based on WHO guidelines. 22 Clinical data, including patient demographics, neurological examinations, tumor eloquence, routine histopathology, and Karnofsky Performance Scale (KPS) scores, were collected from patient records and telephone interviews. This study was approved by the institutional review board of St. Joseph's Hospital and Medical Center.
Three outcome measures were assessed: OS, PFS, and MPFS. Overall survival was defined as the time be tween initial surgery and death. Progression-free survival was defined as the time between initial surgery and demonstration of unequivocal increase in tumor size on follow-up imaging, malignant progression, and/or death. Malignant progressionfree survival was defined as the time between initial surgery and demonstration of Gd enhancement on follow-up imaging and/or higher-grade tumor on subsequent biopsy or death. Patients with no known progression or malignant progression were censored as of their last scan date.
Volumetric EOR Analysis
Manual segmentation was performed with region-ofinterest analysis to measure tumor volumes (in cm 3 ) on the basis of T2-weighted axial MRI slices, as previously described. 30 The EOR was calculated as: (preoperative tumor volume -postoperative tumor volume)/preoperative tumor volume. When present, the volume of enhancing tumor was also measured on preoperative imaging. Determinations of volumes were made by a neuroradiologist without knowledge of clinical outcome.
1p/19q Codeletion Status
Formalinfixed paraffinembedded tissue blocks were analyzed with fluorescence in situ hybridization techniques using probes for 1p36 and 19q13 (Abbott Molecular). For ploidy control, locusspecific probes were used for chromosomes 1 (1q25) and 19 (19p13) . At least 60 cells were analyzed in the targeted region per case. Deletion was scored for 1p36 and 19q13 if the target-ploidy control ratio was less than 0.87, with at least 20% of nuclei showing deletion. These cutoff points exceeded 3 standard deviations from the mean of 20 nonneoplastic control autopsy brain tissue specimens.
Statistical Analysis
Frequency distributions and summary statistics were calculated for all variables. For categorical variables, crosstabulations were generated, and Wilcoxon tests (for ordered variables) and chi-square tests (for nonordered variables) were used to compare their distributions. The Kaplan-Meier method was used to estimate OS, PFS, and MPFS.
Univariate OS, PFS, and MPFS analyses using proportional hazards models 13 were used to assess the prognostic significance of multiple variables. Each measure of tumor burden was assessed separately for predictive value for OS, PFS, and MPFS after adjusting for the effects of age, KPS score, tumor location, and tumor subtype. All p values were from 2tailed tests with statistical significance defined as p < 0.05. In analyses involving multiple categories, to minimize the problem of overstatement of statistical differences resulting from multiple comparisons, individual comparisons were considered for statistical significance only if the overall test was statistically significant. For analyses in which preoperative tumor volume was treated as a continuous variable, log transformation (base 10) was performed to help prevent inappropriate weighting of the results by tumors with large volumes.
To address concerns regarding interobserver variability when evaluating EOR, the EOR measurements were repeated in a blinded fashion, with an additional neuroradiologist to measure preoperative volume, postoperative volume, and EOR in 20 randomly selected patients from our series. Cronbach's alpha and the intraclass correlation coefficient, both statistical measures of internal consistency between data sets, were performed to compare the reliability of measurements between observers.
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Results
Patient Population
Between 1999 and 2010, more than 1500 patients with
LGGs were surgically treated at BNI. Clinical and tumor characteristics of the 93 patients with WHO Grade II oligodendrogliomas who met inclusion criteria are shown in Table 1 . Symptoms at presentation were most commonly seizures (n = 61, 66%), headaches (n = 17, 18%), and visual disturbances (n = 6, 6%). Twenty-three lesions (25%) were located in eloquent territory, and 70 (75%) were found in noneloquent territory. New postoperative deficits, defined as newonset or worsening deficits related to motor, sensory, visual, language, or cognitive function were noted in 28 patients (30%); all but 12 patients (13%) recovered completely ( Table 2 ). There was no treatment-related mortality, and there was not a significant association between EOR and the presence of new postoperative deficit (p = 0.37). During the study period, tumor resections were performed by 9 different BNI neurosurgeons.
Fourteen deaths (15%) occurred, and the median clinical follow-up was 75.4 months. Of those patients who were alive at last follow-up, all underwent follow-up for at least 22 months, and 47 (59%) underwent follow-up for more than 4 years. Progression and malignant progression were identified in 31 (33%) and 20 (22%) cases, 
Contrast enhancement on preoperative imaging was identified in 15 patients (16%). In each case, all contrast enhancing tumor tissue was completely resected, and these areas of enhancement were sent for neuropathology review; no highgrade tumors were identified. Preoperative presence of contrast-enhancing tumor was predictive of OS (p < 0.0001), PFS (p < 0.0001), and MPFS (p < 0.0001). Of these 15 patients, 11 had recurrence of their tumor, all with new enhancement. Seven of these recurrent tumors were identified as being higher grade on subsequent biopsy.
The status of 1p/19q was assessed in 65 patients (70%) using the in situ hybridization methods described above. Of these, 39 patients (42%) demonstrated 1p/19q codeletion. Loss of heterozygosity for only 1p or 19q was observed in 3 cases. Among all specimens, the median MIB-1 proliferative rate was 3 (range 0.1-17).
Patient Outcomes
After adjusting for the effects of age, KPS score, tumor location, MIB-1 index, and 1p/19q codeletion status, the logarithmic value of preoperative tumor volume remained a significant predictor of OS (HR 3. After adjusting for the effects of age, KPS score, tumor location, MIB-1 index, and 1p/19q codeletion status, EOR remained a significant predictor of OS (p = 0.005) and PFS (p = 0.004) but not MPFS. Patients with at least 90% EOR had 5-year OS and PFS rates of 90% and 62%, respectively, whereas patients with less than 90% EOR had 5-year OS and PFS rates of 87% and 41%, respectively. 
Discussion
Although early, aggressive microsurgical resection of LGGs is increasingly common, the optimal role for surgery remains controversial. While recent retrospective studies have uniformly demonstrated survival and PFS benefits associated with greater EOR of LGGs, the impact of cytoreduction on LGG transformation and malignant PFS is less clear. To analyze this relationship in detail, we studied the largest surgical series of WHO Grade II pure oligodendrogliomas reported to date and demonstrate that, for this genetic and histological subtype, tumor transformation rates are unaltered by neurosurgical intervention, even when controlling for molecular signatures such as 1p/19q codeletion.
Interestingly, the documented incidence of LGG transformation ranges widely, from 17% to 73%, in the published literature during the last 15 years, 1, 6, 9, 19, 27, 28, 34, 47 raising the possibility that biological heterogeneity may play a role. Similarly, the observed timing of transformation is highly variable, as reported intervals range from 2.1 to 10.1 years. 3, 6, 21, 26, 34 For both parameters, however, the wide ranges may reflect the fact that every analysis to date has combined multiple LGG subtypes into a single cohort or has used a gross estimate of EOR rather than volumetric analysis. 1, 3, 6, 9, 19, 21, 26, 27, 34, 47 Examples of such studies include an analysis of 216 supratentorial LGGs that reported, for the first time, a predictive relationship between EOR and MPFS. 34 Similarly, a retrospective study of 115 insular gliomas identified a similar association within an anatomical niche. 30 Although both studies included LGG patients treated at the same institution during overlapping periods of time, these investigations also pooled WHO Grade II astrocytoma, oligodendroglioma, and oligoastrocytoma patients together.
Numerous previous reports, including prospective studies, have supported the value of EOR for high-grade gliomas (HGGs). A comparable literature for LGGs is also accumulating, but it lacks Class 1 evidence studies similar to the ALA-Glioma Study Group's analysis of HGG EOR. 35, 36 Nevertheless, in at least 15 studies examining the value of EOR for LGGs, 2, 4, 5, 7, 10, 11, 14, 18, [23] [24] [25] [29] [30] [31] [32] [33] [34] nearly all demonstrated an OS and PFS benefit with greater tumor resection. The identification of an EOR impact on MPFS, however, is a less frequently studied issue, although it has the potential to shift our understanding of LGG resection, as the ability to surgically manipulate the biological tendencies of these tumors would stress earlier neurosurgical intervention and call into question any utility of a wait-andwatch approach. 18 Interestingly, our data confirm the survival benefit associated with greater EOR for pure WHO Grade II oligodendrogliomas, but they do not show it to be predictive of tumor transformation. These results are not necessarily contradictory to previous reports, but instead raise the possibility that the biological effects of EOR may depend upon the molecular background of the lesion. It remains possible that, for oligodendrogliomas, the biological effect of reducing the tumor burden is dissimilar to other WHO Grade II gliomas. Specifically, the genetic and epigenetic mechanisms altered by LGG resection may be unique for each histological subtype-a phenomenon that warrants further investigation, particularly in the context of IDH1/2 mutations. 46 As with other retrospective studies, our findings may be influenced by selection bias, which we attempted to control for by including consecutive patients who met study inclusion criteria. Additionally, variability in clinical management strategies may also impact our results, as all patients were treated on a case-by-case basis with decision making driven by a multidisciplinary team of brain tumor specialists. To control for the effects of disparate treatment paradigms, all patients who were entered in clinical trials were excluded from our analysis. The duration of clinical followup may also confound this study's findings, as the comparatively long natural history of oligodendrogliomas, as well as their slow rate of malignant transformation, necessitate very long intervals of clinical and radiographic follow-up. Although our median follow-up was nearly 7 years, it remains possible that this prolonged interval was still insufficient to detect the true impact of EOR on oligodendroglioma transformation.
Conclusions
Greater EOR is associated with a significant survival benefit for patients with WHO Grade II oligodendrogliomas, but we did not detect a similar effect on MPFS. Taken together, these data raise the possibility that the capacity for microsurgical resection to modulate tumor transformation may be mediated through biological mechanisms specific to nonoligodendroglioma LGG histologies. Our findings challenge previous analyses suggesting that greater LGG EOR impacts MPFS as it relates to the WHO Grade II oligodendroglioma population. However, one cannot conclude that EOR has absolutely no impact on this tumor population as there are many molecular, timing, and treatment factors involved. Although 1p/19q codeletion does not appear to be a molecular variant relevant to EOR, the impact of other biomarkers such as IDH1/2 mutation remains unknown. Prospective tissue collection and molecular profiling of the spectrum of LGG subtypes will be needed to better delineate these mechanisms in the context of neurosurgical intervention.
